Antibody Engineering and Optimization Service
The optimization of antibodies is a crucial step in the drug development process, as it ensures that the finalized antibody candidates possess manufacturability, stability, and retain essential binding and specificity properties. Alfa Cytology offers simultaneous, multifactor antibody engineering and optimization services for bladder cancer antibody candidates.
Introduction to Antibody Engineering and Optimization
Through advanced molecular biology techniques, interested antibodies can be specifically optimized or engineered to suit a particular application. Once the heavy- and light-chain sequences are determined, the antibody of interest can be reconfigured into different isotypes or various formats, such as scFv, Fab, sdAb, and bispecific antibody, through additional modifications including affinity measurement, humanization, canonization, and more. Additionally, antibody engineering can also incorporate phage or other display methods to obtain a broader range of candidates or select the most ideal products for numerous applications.
Fig.1 Representative therapeutic antibodies and their derivatives. (Jin, S., et al. 2022)
Our Services
Empowered by a robust bioinformatics platform, Alfa Cytology offers customers an extensive range of antibody engineering services, encompassing humanization, affinity maturation, Fc engineering, and developability optimization, to acquire superior antibody leads.
Various Antibody Format Engineering Services
In the field of antibody engineering, we understand the importance of different antibody formats in bladder cancer research. Through our diverse antibody format engineering services, we aim to provide solutions tailored to your specific research needs.
We design and develop bispecific and multispecific antibodies to target multiple antigens simultaneously. This approach enhances therapeutic efficacy and offers innovative treatment options for complex diseases such as bladder cancer.
Our expertise extends to the development of Antibody-Drug Conjugates (ADCs), which combine the specificity of antibodies with the potency of cytotoxic drugs. ADCs are designed to deliver targeted cancer therapy, minimizing off-target effects and maximizing therapeutic efficacy in bladder cancer treatment.
Antibody Fragment Engineering
We offer engineering of antibody fragments, including single-chain variable fragments (scFvs) and Fab fragments, to create smaller, more stable, and highly specific therapeutic agents. These fragments can be tailored for better tissue penetration and reduced immunogenicity.
Powerful Antibody Optimization Engineering Services
To ensure the efficacy and specificity of each antibody in bladder cancer research, we offer powerful antibody optimization engineering services.
Antibody Humanization
We specialize in the humanization of monoclonal antibodies to reduce immunogenicity and enhance their compatibility with the human immune system. Our techniques ensure the retention of high affinity and specificity while minimizing potential adverse reactions.
Affinity Maturation
Through affinity maturation, we enhance the binding strength of antibodies to their target antigens. Using techniques such as directed evolution and phage display, we achieve higher affinity and improved therapeutic potential for your antibody candidates.
Antibody Liability Removal
We conduct thorough assessments of antibody stability and developability, identifying and addressing potential issues related to aggregation, solubility, and manufacturability. Our goal is to ensure that your antibody candidates are robust and suitable for large-scale production.
Contact Us
The Alfa Cytology team has dedicated over a decade to the field of bladder cancer antibody engineering and has successfully established a comprehensive range of platforms that integrate various antibody engineering services. With our extensive experience, profound industry knowledge, and advanced technical skills, our scientists are fully confident in accomplishing even the most challenging projects in antibody engineering.
If you are interested in our antibody engineering and optimization service, please contact us today.
Reference
- Jin, S., Sun, Y., and et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal transduction and targeted therapy, 2022, 7(1), 39.
For research use only. Not intended for any clinical use.
Related Services
